Neil Marouka

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell 2.6 percent Wednesday as the Street reacted to an ostensible downgrade. Canaccord Genuity’s John Newman had long been confidently bullish on the stock, so when a new note updated coverage with a “speculative” Buy, traders...

“Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has taken its first significant steps toward de-levering its balance sheet, announcing the divestiture of Dendreon and several dermatology brands for combined cash consideration of ~2.1 billion,” Canaccord Genuity’s Neil Marouka said...